Entera Bio LTD. (ENTX) — SEC Filings

Overview

Entera Bio LTD. (ENTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Entera Bio Ltd. (ENTX) reported a net loss of $8.423 million for the nine months ended September 30, 2025, an increase from the $7.183 million net loss in the same period of 2024. Revenue decreased significantly to $42 thousand for the nine months ended September 30, 2025, down from $99 thousand in

Sentiment Summary

Across 22 filings, the sentiment breakdown is: 20 neutral, 2 mixed. The dominant filing sentiment for Entera Bio LTD. is neutral.

Filing Type Overview

Entera Bio LTD. (ENTX) has filed 5 10-Q, 9 8-K, 2 DEF 14A, 2 10-K, 1 8-K/A, 3 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (22)

• Entera Bio's Q3 Loss Widens Amid R&D Spend, Revenue Dries Up — 10-Q · Nov 14, 2025 Risk: high
  Entera Bio Ltd. (ENTX) reported a net loss of $8.423 million for the nine months ended September 30, 2025, an increase from the $7.183 million net loss in the s
• Entera Bio Ltd. Files 8-K on Financials and Warrants — 8-K · Aug 8, 2025 Risk: medium
  Entera Bio Ltd. filed an 8-K on August 8, 2025, reporting on its financial condition and results of operations. The filing also includes Regulation FD disclosur
• Entera Bio Ltd. Files 8-K on Warrants and Operations — 8-K · Jul 28, 2025 Risk: medium
  Entera Bio Ltd. filed an 8-K on July 28, 2025, reporting on various events. The filing includes information about warrants exercisable for Ordinary Shares at an
• Entera Bio Ltd. Files 8-K on Shareholder Vote Matters — 8-K · Jul 18, 2025 Risk: medium
  Entera Bio Ltd. filed an 8-K on July 18, 2025, reporting a submission of matters to a vote of security holders on July 16, 2025. The company is involved in biol
• Entera Bio Shares Soar 212% in 2 Years Amidst Executive Pay Disclosures — DEF 14A · Jun 5, 2025 Risk: medium
  Entera Bio Ltd.'s DEF 14A filing, dated June 5, 2025, primarily details executive compensation and its relationship to company performance, specifically focusin
• Entera Bio Ltd. Q1 2025 10-Q Filed — 10-Q · May 9, 2025 Risk: low
  Entera Bio Ltd. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including changes i
• 10-K Filing — 10-K · Mar 28, 2025
• Entera Bio Ltd. Discloses Warrant Agreement and Equity Sales — 8-K · Mar 17, 2025 Risk: medium
  Entera Bio Ltd. announced on March 16, 2025, the entry into a material definitive agreement related to warrants. These warrants are exercisable for half of an O
• Entera Bio Ltd. Files 8-K on Warrants — 8-K · Jan 10, 2025 Risk: low
  Entera Bio Ltd. filed an 8-K on January 10, 2025, reporting on financial statements and exhibits. The filing details warrants exercisable for half an Ordinary S
• Entera Bio Ltd. Amends Filing on Shareholder Votes and Warrants — 8-K/A · Dec 20, 2024 Risk: low
  Entera Bio Ltd. filed an amendment (8-K/A) on December 20, 2024, related to events on July 31, 2024. The filing concerns matters submitted to a vote of security
• SC 13G/A Filing — SC 13G/A · Nov 20, 2024
• Entera Bio Ltd. Files Q3 2024 10-Q — 10-Q · Nov 8, 2024 Risk: medium
  Entera Bio Ltd. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business activities.
• SC 13G/A Filing — SC 13G/A · Aug 20, 2024
• Entera Bio Ltd. Files Q2 2024 10-Q Report — 10-Q · Aug 9, 2024 Risk: medium
  Entera Bio Ltd. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business activities. Spec
• Entera Bio Ltd. Raises $10M via Share and Warrant Offering — 8-K · Aug 2, 2024 Risk: medium
  Entera Bio Ltd. announced on July 31, 2024, that it has entered into a securities purchase agreement to sell approximately $10.0 million of its ordinary shares
• Entera Bio Ltd. Executive Compensation Details Revealed — DEF 14A · Jun 20, 2024 Risk: low
  Entera Bio Ltd. filed a DEF 14A detailing executive compensation for 2023 and 2022. Miranda Toledano served as Executive Officer, with Hillel Galitzer and Dana
• Entera Bio Ltd. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  Entera Bio Ltd. (ENTX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Entera Bio Ltd. filed a 10-Q report for the period ending March 31, 2024. T
• Entera Bio Ltd. Files 2023 Annual Report on Form 10-K — 10-K · Mar 8, 2024 Risk:
  Entera Bio Ltd. (ENTX) filed a Annual Report (10-K) with the SEC on March 8, 2024. Entera Bio Ltd. filed its annual report on Form 10-K for the fiscal year ende
• Entera Bio Ltd. Warrants Listed on NASDAQ — 8-K · Mar 4, 2024 Risk: medium
  Entera Bio Ltd. announced on March 4, 2024, that its warrants, exercisable for half an Ordinary Share at $5.85, are listed on NASDAQ under the ticker ENTXW. Thi
• Entera Bio Details Warrants: $5.85 Exercise Price Per Share — 8-K · Feb 2, 2024
  Entera Bio Ltd. filed an 8-K on February 2, 2024, disclosing information about its Warrants, which are exercisable for half of an Ordinary Share at an exercise
• Knoll Capital Amends Entera Bio Stake as of Dec 26, 2023 — SC 13G/A · Jan 16, 2024
  Knoll Capital Management, LLC, a Miami-based investment firm, has updated its ownership stake in Entera Bio Ltd. (NASDAQ: ENTX) as of December 26, 2023. This am
• Entera Bio Warrants (ENTXW) Exercisable at $5.85/Share — 8-K · Jan 3, 2024
  On January 3, 2024, Entera Bio Ltd. filed an 8-K to report that its warrants, trading under the symbol ENTXW on NASDAQ, are each exercisable for half of an Ordi

Risk Profile

Risk Assessment: Of ENTX's 15 recent filings, 1 were flagged as high-risk, 9 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Entera Bio LTD.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $42K
• Net Income: -$8.423M
• EPS: N/A
• Debt-to-Equity: 0.14
• Cash Position: $8.574M
• Operating Margin: N/A
• Total Assets: $17.407M
• Total Debt: $2.173M

Key Executives

• Hillel Galitzer
• Dana Yaacov-Garbeli
• Miranda Toledano

Industry Context

Entera Bio operates in the highly competitive biotechnology sector, focusing on developing novel therapeutics for significant unmet medical needs. The industry is characterized by long development cycles, substantial R&D investment, and high regulatory hurdles. Success often hinges on clinical trial outcomes and securing strategic partnerships or funding to advance pipeline candidates through various stages of development.

Top Tags

warrants (10) · 10-Q (4) · Biotechnology (3) · financials (3) · sec-filing (2) · shareholder-vote (2) · Executive Compensation (2) · biotech (2) · amendment (2) · dilution (2)

Executive Compensation

From the most recent DEF 14A filing (Jun 5, 2025):

• Not Disclosed — Principal Executive Officer: Not Disclosed
• Hillel Galitzer — Non-PEO NEO: Not Disclosed
• Dana Yaacov-Garbeli — Non-PEO NEO: Not Disclosed

Key Numbers

• Net Loss (9 months): $8.423M — Increased from $7.183M in 2024, indicating widening losses.
• Revenue (9 months): $42K — Decreased from $99K in 2024, showing a significant drop in income.
• R&D Expenses (9 months): $4.286M — Increased from $3.298M in 2024, reflecting higher investment in clinical trials.
• Cash & Cash Equivalents: $8.574M — Slightly down from $8.660M at year-end 2024, but restricted cash increased.
• Accumulated Deficit: $122.4M — Increased from $113.927M at year-end 2024, highlighting ongoing losses.
• Net Cash Used in Operating Activities (9 months): $5.537M — Increased from $5.351M in 2024, indicating higher cash burn.
• Ordinary Shares Outstanding: 45,857,242 — As of November 10, 2025, up from 38,837,220 at Dec 31, 2024, indicating dilution.
• Net Cash Provided by Financing Activities (9 months): $13.536M — Significantly up from $1.259M in 2024, primarily from share issuances.
• Warrant Exercise Price: $5.85 — Price at which ENTXW warrants can be exercised for half an ordinary share.
• Ordinary Share closing price: $2.28 — on December 31, 2024, up from $0.73 on December 31, 2022
• Stock price increase: 212% — from December 31, 2022, to December 31, 2024
• End of Reporting Period: 2025-03-31 — Marks the end of the financial quarter being reported.
• Filing Date: 2025-05-09 — Date the 10-Q was officially submitted to the SEC.
• Capital Raise: $10.0M — Amount raised through sale of ordinary shares and warrants.
• Period End Date: 2024-03-31 — Quarterly report period

Related Companies

OPK · ENTXW

Frequently Asked Questions